December 1990

Does Somatostatin Analogue Prevent Experimental Acute Pancreatitis?

Author Affiliations

From the Surgical and Research Services, Veterans Affairs Lakeside Medical Center and the Department of Surgery, Northwestern University Medical School, Chicago, Ill (Drs Murayama and Joehl and Mr Drew).

Arch Surg. 1990;125(12):1570-1572. doi:10.1001/archsurg.1990.01410240048011

• Because somatostatin is a potent inhibitor of pancreatic secretion, we hypothesized that pretreatment with somatostatin analogue octreotide (SMS 201-995) might prevent cerulein-induced edematous pancreatitis. We studied 18 rats prepared with jugular vein catheters. The following agents were administered intravenously to groups of four rats for 6 hours: 1 mL/h (control) crystalloid solution; 1-μg/kg bolus then 1 μg/kg per hour of octreotide; and 5 μg/kg per hour of cerulein; also, in a fourth group of six rats, octreotide and cerulein were administered simultaneously. At the end of experiments, blood was drawn for plasma amylase determinations; rats were killed and pancreata were examined. Supramaximal cerulein administration to conscious rats induced hyperamylasemia and edematous pancreatitis, confirming previous observations; in both groups of rats receiving cerulein, there was prominent interstitial edema, acinar vacuolization, and mild-to-moderate acute inflammation. While octreotide pretreatment of rats with cerulein-induced acute pancreatitis was associated with a lesser increase of wet pancreas weight and plasma amylase concentration, there was little overall benefit of octreotide pretreatment in this form of experimental acute pancreatitis.

(Arch Surg. 1990;125:1570-1572)